Get the Stockscreener App
0.00
100.00%
-14.84
89 Bio Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
See More
Previous Close:
$14.84
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$2.20B
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
0.00
EPS:
-1.97
Net Cash Flow:
$-165.54M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$15.06
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
655 MONTGOMERY STREET, SAN FRANCISCO, CA
Compare ETNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
0.00 | 2.20B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Resumed | BofA Securities | Buy |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-10-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-23 | Initiated | UBS | Buy |
| Jun-13-23 | Initiated | Evercore ISI | Outperform |
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
Is 89bio Inc. stock dividend yield sustainable2025 Major Catalysts & Smart Swing Trading Techniques - BỘ NỘI VỤ
[EFFECT] 89bio, Inc. SEC Filing - Stock Titan
89bio Acquisition Finalized: Roche Completes Takeover () - aktiencheck.de
[Form 4] 89bio, Inc. Insider Trading Activity - Stock Titan
Fatty liver disease companies' multibillion-dollar deals mean fatter wallets - The Business Journals
ETNB CEO Form 4 details Roche deal payout and option treatment - Stock Titan
ETNB officer reports tender offer completion; shares exchanged for $14.50 + CVR - Stock Titan
[POSASR] 89bio, Inc. SEC Filing - Stock Titan
Roche Holdings completes acquisition of 89bio and delists company from Nasdaq - Investing.com
Roche completes 89bio deal; ETNB holders get $14.50 cash + CVR - Stock Titan
89bio acquired by Roche with $14.50 cash and up to $6 CVR - Stock Titan
Roche purchases shares in tender offer for 89bio, Inc - The Manila Times
Roche (OTCQX: RHHBY) accepts 60.49% of 89bio shares, plans merger at $14.50 + CVR - Stock Titan
89bio, Inc.(NasdaqGM: ETNB) dropped from S&P Biotechnology Select Industry Index - MarketScreener
Roche Holding AG completed the acquisition of 89bio, Inc. in a tender offer transaction. - MarketScreener
ETNB CFO option exercises update direct holdings to 339,295 shares - Stock Titan
[SC TO-T/A] 89bio, Inc. Amended Third-Party Tender Offer | ETNB SEC FilingForm SC TO-T/A - Stock Titan
Will 89bio Inc. stock split attract more investorsTrade Analysis Report & Safe Entry Zone Tips - Trung tâm Dự báo KTTV quốc gia
How strong is 89bio Inc. stock balance sheetEarnings Risk Summary & Fast Moving Stock Watchlists - Trung tâm Dự báo KTTV quốc gia
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (NasdaqETNB), Barinthus Biotherapeutics plc (NasdaqBRNS), Verint Systems Inc. (Nasdaq - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Combining price and volume data for 89bio Inc.Layoff News & Long-Term Growth Stock Strategies - newser.com
Will 89bio Inc. stock benefit from AI adoption2025 Geopolitical Influence & Weekly Top Performers Watchlists - newser.com
89bio, Inc. (ETNB) Stock Analysis: Unveiling A 97% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Janus Henderson Reports 5,378,185 Shares, 3.6% Stake in 89bio - Stock Titan
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc.ETNB - Business Wire
Investors Purchase High Volume of Put Options on 89BIO (NASDAQ:ETNB) - Defense World
After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks - Fierce Biotech
Roche commences tender offer for all shares of 89bio, Inc. - GlobeNewswire
$20.50 Per Share Deal: Roche Makes Move to Acquire 89bio in Major Biotech Tender Offer - Stock Titan
89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal - MSN
Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR - Nasdaq
Kala Bio Stock Just Plunged 89% Today – Here’s What Happened - Stocktwits
Why 89bio Inc. stock is rated strong buy2025 Biggest Moves & Verified Entry Point Detection - newser.com
Technical analysis overview for 89bio Inc. stock2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Is 89bio Inc. stock attractive for retirement portfoliosWeekly Stock Report & Momentum Based Trading Ideas - newser.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PINC, MTSR, ETNB on Behalf of Shareholders - GlobeNewswire Inc.
Backtesting results for 89bio Inc. trading strategiesQuarterly Trade Review & Short-Term High Return Strategies - newser.com
How 89bio Inc. stock reacts to global recession fearsBear Alert & Community Consensus Picks - newser.com
Measuring 89bio Inc.’s beta against major indicesEarnings Overview Report & Daily Profit Maximizing Trade Tips - newser.com
89bio, Inc. Hits New 52-Week High of $15.06, Up 76.62% - Markets Mojo
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB) - PR Newswire
How to integrate 89bio Inc. into portfolio analysis toolsJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Applying chart zones and confluence areas to 89bio Inc.Forecast Cut & Free Technical Pattern Based Buy Signals - newser.com
Real time breakdown of 89bio Inc. stock performance2025 Historical Comparison & Entry Point Strategy Guides - newser.com
Roche To Buy 89bio For Up To $3.5 Billion - Pulse 2.0
89Bio (ETNB) Soars 86 Percent to Historic High on $3.5-Billion Roche Merger - MSN
Will 89bio Inc. continue its uptrendPortfolio Update Summary & Verified High Yield Trade Plans - newser.com
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):